Anavex Life Sciences Corp (AVXL)

[Hoskuld]

I think you are right that there was no intent to run a 2nd P3: there is plenty of evidence 2-73 works for AD clinically, and biomarker evidence makes it all the more likely that approval will happen relatively quickly. A P4 is what makes sense when there is a huge unmet need and strong evidence that a relatively inexpensive approach (compared to IV infusions of mAbs) works better than all existing therapies.